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Background: The counting of poorly differentiated clusters of 5 or more cancer cells lacking a gland-like structure
in a tumor mass has recently been identified among the histological features predictive of poor prognosis in
colorectal cancer.
Main body: Poorly differentiated clusters can easily be recognized in the histological sections of colorectal cancer
routinely stained with haematoxylin and eosin. Despite some limitations related to specimen fragmentation,
counting can also be assessed in endoscopic biopsies. Based on the number of poorly differentiated clusters that
appear under a microscopic field of a ×20 objective lens (i.e., a microscopic field with a major axis of 1 mm),
colorectal cancer can be graded into malignancies as follows: tumors with <5 clusters as grade 1, tumors with 5 to
9 clusters as grade 2, and tumors with ≥10 clusters as grade 3. High poorly differentiated cluster counts are
significantly associated with peri-neural and lympho-vascular invasion, the presence of nodal metastases or
micrometastases, as well as shorter overall and progression free survival to colorectal cancer.
Conclusion: The morphological aspects and clinical relevance of poorly differentiated clusters counting in
colorectal cancer are discussed in this review.
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The incidence of colorectal cancer (CRC) has gradually
increased over the decades in developed countries, and is
now the third most-commonly diagnosed cancer [1–4].
In histopathological routine practice, tumor grade
represents one of the most important predictive factors
of colorectal cancer (CRC) aggressiveness [5]. To date,
the most widely used system of defining CRC’s histo-
logical grade is based on the percentage of tumor glands
forming the mass. However, this system suffers from
significant inter-observer variability due to the lack of
objective methods with which to assess the amount of
glandular components [6].
More recently, a novel histological grading system
has been highlighted as a histopathological prognosti-
cator of CRC. This system considers poorly differentiated* Correspondence: cristian.palmiere@chuv.ch
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vasive front of the tumor that lack full glandular forma-
tion, [1, 4, 7–9].
Main text
PDC can be evaluated in representative haematoxylin
and eosin (H&E) stained slides that include the advan-
cing edge of the tumor counted in the microscopic field
under a ×20 objective lens (i.e. a 1 mm microscopic
field). CRC can then be categorized into three grades of
malignancy based on the highest PDC count: grade 1
(G1) count less than 5 (Fig. 1a), grade 2 (G2) range be-
tween 5 and 9 (Fig. 1b) and grade 3 (G3) 10 or more PDC
clusters found (Fig. 1c).
Although PDC and tumor budding are similar in morph-
ology given that neither have gland silhouettes, they repre-
sent two different entities. Indeed, by definition, tumor
budding foci are smaller than PDC and made up of iso-
lated cancer cells or small clusters of fewer than 5 ele-
ments [7, 10]. Thus, PDC are more easily recognizablehis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 1 Grades of malignancy of CRC based on the highest PDC count. a PDC G1: <5 clusters [H&E stain 10×]. The particular of the clusters
showing more than 5 undifferentiated cancer cells [asterisk - H&E stain 20×]. b PDC G2: 5–9 clusters [H&E stain 20×]. c PDC G3: ≥ 10 clusters at
the fron of the tumor mass [H&E stain 10×]. d PDC G3: The same clusters at major resolution [H&E stain; 20×]
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munohistochemical stains, such as cytokeratins. On the
other hand, immunohistochemistry is mandatory for
correct tumor budding identification, especially when it
can be masqueraded by peritumoral desmoplastic tissue
or inflammatory cell accumulation, as in leukocyte-rich
peritumoral stroma [10–12].
The lack of information regarding PDC development
has allowed for different hypothesis regarding their
pathogenesis to be made. Their similar morphology sug-
gests that PDC and tumor budding could represent se-
quential steps in tumor growth. This hypothesis is
supported by the evidence of both PDC and tumor bud-
ding in the same tumor mass. This may serve as proof
of possible sequential transformation of the latter into
the former. Several studies in vitro have shown that
tumor cells, singly or in large aggregates, can detach
from the tumor mass and migrate into desmoplastic
extracellular matrix with cohort-migration or through a
mesenchymal-amoeboid transformation, activating an
epithelial-mesenchymal transition process [13–19]. Ac-
cording to this development, PDC could represent the
evolution of tumor buds or tumor podia, while they ac-
quire proliferative and aggregative strength. Thus, PDC
have been strongly associated with the up-regulation of
Wnt/beta-catenin signaling pathways, such as metallo-
proteinase, disintegrin and L1-cell-adhesion-molecule
(LICAM) [8, 20, 21] or beta-catenin [8, 20–22] as wellas with the loss of pro-adhesion proteins such as caderin
E [22, 23] or claudin [24]. These findings encourage the
considerazion of PDC as directly involved in tumor dis-
semination and metastasis formation through direct inva-
sion of lymph vascular channels. PDC could consequently
assume a fundamental role in the definition of cancer ag-
gressiveness and prediction of tumor behavior.
Recent studies have shown that PDC are strongly asso-
ciated with vascular lymph invasion and lymph nodal me-
tastases. Furthermore, they predict N+ status with higher
sensitivity and specificity compared to other traditional,
unfavorable histological factors of prognosis [25–27].
This data has been demonstrated in all TNM stages,
including the early (pT1) CRC where PDC are corre-
lated with tumor depth, particularly sub-mucosal inva-
sion ≥ 1000 μn [27, 28].
These results encourage considering the presence and
number of PDC as possible tools in risk assessment per-
taining to nodal involvement. This is especially useful when
conservative, local excision of low rectal carcinoma is used,
when the lymph nodes cannot be examined or the number
of examined lymph nodes is less than 12 (the minimum
recommended for accurate staging in CRC) [27]. Further-
more, PDC grade has been reported as a significant
predictor of occult micrometastases, defined as small meta-
static deposits measuring less than 2 mm in a greater diam-
eter detectable by immunohistochemistry or reverse
transcription polymerase chain reaction in otherwise node
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demonstrated that PDC grade is significantly associated
with the presence of lymph node micrometastases and
may therefore be used in case selection cases for time-
consuming, costly evaluation of occult nodal micrometas-
tasis [27].
PDC’s efficacy in categorizing patients affected by CRC
for prognosis has been evaluated in different studies. PDC
grading has been demonstrated as a strong, independent
prognostic factor in CRC [12, 26–29], where the high
number of PDC (PDC G2 CRC and PDC G3 CRC) is
strongly predictive of short, disease free survival and short
disease specific survival, independent of pTNM stages [7,
28] and other unfavorable histological features, including
traditional conventional WHO grading [7, 8, 26–29].
PDC-grading appeared more accurate in identifying
stage I, subgroup with poor survival. Indeed, patients with
stage I PDC-rich tumors have been shown to have an over-
all survival comparable to, or worse than that observed in
subjects with stage III CRCs [9, 26, 27]. This data is rele-
vant in oncological practice for this category of patients as
well as in stage IIA subjects, in whom the post-surgical ap-
plication of chemotherapy is controversial [25, 26].
Tumor grading based on PDC counting is applicable
in more than 90 % of CRC endoscopic biopsies. It can
reveal relevant information about the anatomical extent
of the disease as well as biological proprieties of the
tumor. When compared to traditional tumor grading,
PDC-grading is more accurate in this context. In par-
ticular, high numbers of PDC in biopsy specimens are
strongly predictive of unfavorable histological features,
including infiltrating tumor borders, tumor budding,
lymph vascular invasion, and perineural invasion in resec-
tion specimens, suggesting more aggressive behavior [25].
Similar to that observed in surgical specimens, a positive
inter-observer agreement may be reached in the assess-
ment of histological PDC grading in biopsy, which is
higher than that achieved by using a conventional grading
system [29]. These results may have remarkable clinical
relevance in the choice of therapeutic management for pa-
tients affected by CRC, with particular regards to those
with rectal cancer. Indeed, tumors with a low PDC grade
could be submitted to local excision, whereas more inva-
sive procedures, including anterior resection, might be re-
served for those displaying a high number of PDC [30, 31].
Although PDC counting in biopsy has revealed a sig-
nificant correlation with the corresponding surgical spe-
cimen that would suggest a lower number, there have
been criticisms that the number of detectable clusters at
biopsy may appear less since samples may not be taken
from the deepest part of the tumor. Other problems en-
countered in PDC counting in biopsies are high tissue
fragmentation, possible extensive necrosis, mainly in ul-
cerated tumors. Beyond these criticisms, thermal electrocoagulation-induced cytological artifacts may reduce the
quantity of evaluable cancer tissue and induce difficulties
in PDC detection [25, 29]. The main difficulty is the dis-
tinction of PDC from transversally cut glandular crypts.
These conditions increase confounding features and pro-
voke discordance in PDC evaluation. However, bias can
be avoided by excluding necrotic areas from the count
and carefully considering all fragmented cluster cells de-
tached from the sample using a critical approach.
A high PDC count has been significantly associated
with CRC’s mutational status; in particular with KRAS
mutation. The most frequent mutations have been ob-
served in G12A and G12C in codon 12, and G13C and
G13D in codon 13. These data give insight into the
mechanisms of PDC development supposing that KRAS
mutations might be responsible for their formation. The
association of a KRAS mutation and high PDC grade, a
higher depth colonic wall invasion and development of
nodal metastases may account for a poorer prognosis of
KRAS mutated CRC [32]. Although with no statistical
significance, a similar trend has been viewed with V600E
BRAF mutation.
Conclusion
Due to its positive reproducibility and ease of histo-
logical detection, PDC are destined to assume more and
more relevance in the histopathological description of
CRC, as well as in clinical and oncological practice. Al-
though no worldwide consensus has been reached thus
far, PDC may foreseeable be introduced in a histological
report, considered with other, commonly noted unfavor-
able histological features, to give further, important prog-
nostic information for patient management.
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